{
    "id": "622629d13a8413c65300007e",
    "question": "Can FTO promote pancreatic cancer development?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the relationship between the FTO gene and pancreatic cancer development. The FTO gene is associated with obesity and has been identified as a risk factor for various types of cancer, including pancreatic cancer. However, the question is whether FTO can directly promote pancreatic cancer development. Step 1: Review the available documents to find any information about the FTO gene and its relationship to pancreatic cancer. Step 2: After reviewing the documents, we can see that there is no direct information about the FTO gene promoting pancreatic cancer development. However, the FTO gene is associated with obesity, which is a risk factor for pancreatic cancer. Step 3: Consider the relationship between obesity and pancreatic cancer. Obesity is a known risk factor for pancreatic cancer, but it is not a direct cause of the disease. Step 4: Based on the available information, it appears that FTO is not a direct promoter of pancreatic cancer development. Instead, it is associated with obesity, which is a risk factor for pancreatic cancer. Step 5: Conclusion: Based on the available information, the correct answer is B. no, FTO does not promote pancreatic cancer development.\"} \"answer_choice\": \"B\"",
    "snippets": [
        {
            "id": "InternalMed_Harrison_7167",
            "title": "InternalMed_Harrison",
            "content": "The early detection and future treatment of pancreatic cancer relies on an improved understanding of molecular pathways involved in the development of this disease. This will ultimately lead to the discovery of novel agents and the identification of patient groups who are likely to benefit most from targeted therapy. Dr. Irene Chong is acknowledged for her work on this chapter in the 18th edition."
        },
        {
            "id": "Surgery_Schwartz_9786",
            "title": "Surgery_Schwartz",
            "content": "cancer. The etiology of pancreatic cancer likely involves a complex interaction of genetic and environmental factors. These factors will become more fully understood as DNA sequencing is used to screen populations at risk for developing pancreatic cancer.Pancreatic cancer is more common in older adults with most patients being 75 to 84 years old. Pancreatic cancer is more common in African Americans and slightly more com-mon in men than women. The risk of developing pancreatic cancer is two to three times higher if a parent or sibling had the disease. Another risk factor that is consistently linked to pan-creatic cancer is cigarette smoking. Smoking increases the risk of developing pancreatic cancer by at least twofold due to the carcinogens in cigarette smoke.308 Coffee and alcohol consump-tion have been investigated as possible risk factors, but the data are inconsistent. As in other GI cancers, diets high in fat and low in fiber, fruits, and vegetables are thought to be associated"
        },
        {
            "id": "Surgery_Schwartz_9975",
            "title": "Surgery_Schwartz",
            "content": "2012;95:120-134. 305. Mazzaglia PJ, Berber E, Milas M, et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142:10-19. 306. Kotteas EA, Syrigos KN, Saif MW. Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors. Onco Targets Ther. 2016;9:699-704. 307. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2014. Bethesda, MD: National Cancer Institute. Available at: https://seer.cancer.gov/csr/1975_2014/. Accessed July 30, 2018. 308. Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am. 1998;7:67-91. 309. Fisher WE. Diabetes. Risk factor for the development of pancreatic cancer or manifestation of the disease? World J Surg. 2001;25:503-508. 310. Jean M, Lowy A, Chiao P, et al. The Molecular Biology of Pancreatic Cancer. New York: Springer-Verlag; 2002. 311. Berger"
        },
        {
            "id": "Pathology_Robbins_4114",
            "title": "Pathology_Robbins",
            "content": "Pancreatic cancer is primarily a disease of older adults, with 80% of cases occurring between 60 and 80 years of age. The strongest environmental influence is smoking, which doubles the risk. Long-standing chronic pancreatitis and diabetes mellitus are also associated with a modestly increased risk for pancreatic cancer. These two entities have a bidirectional link with pancreatic cancer. Thus, for example, tumors arising in the head of the pancreas often cause chronic pancreatitis in the distal parenchyma, while diabetes caused by duct obstruction and subsequent pancreatitis may be the manifestation of an underlying neoplasm. In fact, approximately 1% of the older adult population with new-onset diabetes harbor an unsuspected pancreatic cancer. Familial clustering of pancreatic cancer has been reported, and a growing number of inherited genetic defects are now recognized that increase pancreatic cancer risk. For example, germ line mutations of the familial breast/ ovarian cancer gene"
        },
        {
            "id": "Surgery_Schwartz_9785",
            "title": "Surgery_Schwartz",
            "content": "of all malignancies with a 5-year survival rate of only 7.2%.307 The incidence of pancreatic cancer continues to increase, perhaps related to the increased incidence of risk factors such as obesity and diabetes, and as a result, it is predicted that pancreatic cancer will become the leading cause of cancer deaths in the United States by 2050. Pancreatic cancer recently surpassed breast cancer and is now the third leading cause of cancer death behind lung and colorectal cancer. Despite its ubiquity, this dis-ease is extremely difficult to treat, and its exact cause is unknown. However, epidemiologic studies linking various environmental and host factors provide some clues. Recent discoveries using modern molecular biologic techniques have also improved our understanding of the causes of pancreatic cancer. The etiology of pancreatic cancer likely involves a complex interaction of genetic and environmental factors. These factors will become more fully understood as DNA sequencing is used"
        },
        {
            "id": "Surgery_Schwartz_9976",
            "title": "Surgery_Schwartz",
            "content": "cancer or manifestation of the disease? World J Surg. 2001;25:503-508. 310. Jean M, Lowy A, Chiao P, et al. The Molecular Biology of Pancreatic Cancer. New York: Springer-Verlag; 2002. 311. Berger D, Fisher W. Inherited Pancreatic Cancer Syndromes. New York: Springer-Verlag; 2002. 312. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399-405. 313. Biankin AV, Kench JG, Dijkman FP, et al. Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma. Pathology. 2003;35(1):14-24. 314. Wilentz RE, Hruban RH. Pathology of cancer of the pancreas. Surg Oncol Clin N Am. 1998;7:43-65. 315. Ritts R, Pitt H. CA19-9 in pancreatic cancer. Surg Oncol Clin N Am. 1998;7:93-101. 316. Kung-Kai Kuo, Chao-Jen Kuo, Chiang-Yen Chiu, et al. Quantitative proteomic analysis of differentially expressed protein profiles involved in pancreatic ductal adenocarcinoma pancreas."
        },
        {
            "id": "Surgery_Schwartz_9791",
            "title": "Surgery_Schwartz",
            "content": "analysis of 99 tumors reaffirmed the importance of the already known mutations such as KRAS, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A, and SF3B1 in pancreatic cancer and identified eight novel significantly mutated genes involved in chromatin modification (EPC1 and ARID2), DNA dam-age repair (ATM) and other mechanisms (ZIM2, MAP2K4, NALCN, SLC16A4, and MAGEA6). Pathway-based analysis of recurrently altered genes also revealed the involvement of axon-guidance genes, particularly SLIT/ROBO signaling, in pancreatic carcinogenesis.312 Rapid and sensitive sequencing techniques will hopefully lead to better diagnostic and thera-peutic approaches for pancreatic cancer.It is estimated that up to 10% of pancreatic cancers occur as a result of an inherited genetic predisposition. A family his-tory of pancreatic cancer in a first-degree relative increases the risk of pancreatic cancer by about twofold. Rare familial cancer syndromes that are associated with an increased risk of pancreatic"
        },
        {
            "id": "InternalMed_Harrison_7142",
            "title": "InternalMed_Harrison",
            "content": "An estimated 278,684 cases of pancreatic cancer occur annu ally worldwide (the thirteenth most common cancer globally), with up to 60% of these cases diagnosed in more developed countries. It remains the eighth most common cause of cancer death in men and the ninth most common in women. The incidence is highest in the United States and western Europe and lowest in parts of Africa and South Central Asia. However, increasing rates of obesity, diabetes, and tobacco use in addition to access to diagnostic radiology in the developing world are likely to increase incidence rates in these countries. In this situation, consideration of the cost implications of adoption of current treatment paradigms in resource-constrained environments will be necessary. Primary prevention such as limiting tobacco use and avoiding obesity may be more cost effective than improvements in treatment of preexisting disease."
        },
        {
            "id": "Pathology_Robbins_4108",
            "title": "Pathology_Robbins",
            "content": "Infiltrating ductal adenocarcinoma of the pancreas (more commonly referred to as pancreatic cancer) is the third leading cause of cancer deaths in the United States, preceded only by lung and colon cancers. Although it is substantially less common than the other two malignancies, pancreatic carcinoma is near the top of the list of killers because it carries one of the highest mortality rates. Close to 49,000 Americans were diagnosed with pancreatic cancer in 2015, and virtually all will die in a short period after diagnosis; the 5-year survival rate is a dismal 8%. http://ebooksmedicine.net Like all cancers, pancreatic cancer arises as a consequence of inherited and acquired mutations in cancer-associated"
        },
        {
            "id": "InternalMed_Harrison_7141",
            "title": "InternalMed_Harrison",
            "content": "Pancreatic cancer represents 3% of all newly diagnosed malignancies in the United States. The most common age group at diagnosis is 65\u201384 years for both sexes. Pancreatic cancer was estimated to have been diagnosed in approximately 45,220 patients and accounted for approximately 38,460 deaths in 2013. Although survival rates have almost doubled over the past 35 years for this disease, overall survival remains low."
        },
        {
            "id": "Surgery_Schwartz_9787",
            "title": "Surgery_Schwartz",
            "content": "have been investigated as possible risk factors, but the data are inconsistent. As in other GI cancers, diets high in fat and low in fiber, fruits, and vegetables are thought to be associated with an increased risk of pancreatic cancer.Diabetes has been known to be associated with pancreatic cancer for many years. In fact, glucose intolerance is present in 80% of patients with pancreatic cancer, and approximately 20% have overt diabetes, a much greater incidence than would be expected to occur by chance. Preexisting type 2 diabetes increases the risk for development of pancreatic cancer by about twofold.309 The new onset of diabetes also can be an early mani-festation of otherwise occult pancreatic cancer. Thus, the new onset of diabetes, or a sudden increase in insulin requirement in an older adult patient with preexisting diabetes, should provoke concern for the presence of pancreatic cancer.Recent epidemiologic studies have confirmed the fact that patients with chronic"
        },
        {
            "id": "InternalMed_Harrison_7140",
            "title": "InternalMed_Harrison",
            "content": "Elizabeth Smyth, David Cunningham Pancreatic cancer is the fourth leading cause of cancer death in the United States and is associated with a poor prognosis. Endocrine tumors affecting the pancreas are discussed in Chap. 113. Infiltrating ductal adenocarcinomas, the subject of this Chapter, account for the vast majority of cases and arise most frequently in the head of pancreas. At the time of diagnosis, 85\u201390% of patients have inoperable or metastatic disease, which is reflected in the 5-year survival rate of only 6% for all stages combined. An improved 5-year survival of up to 24% may be achieved when the tumor is detected at an early stage and when complete surgical resection is accomplished."
        },
        {
            "id": "Surgery_Schwartz_2169",
            "title": "Surgery_Schwartz",
            "content": "do not appear to alter its function increase the risk of melanoma by 38-fold and do not increase the risk of pancreatic cancer.83 Genomic characterization of primary tumors has revealed that p16 is inactivated through point mutation, promoter methyla-tion, or deletion in a significant portion of sporadic tumors, including cancers of the pancreas, esophagus, head and neck, stomach, breast, and colon, as well as melanomas.E-cadherin and Hereditary Diffuse Gastric Cancer. E-cadherin is a cell adhesion molecule that plays an important role in nor-mal architecture and function of epithelial cells. The adhesive function of E-cadherin is dependent on interaction of its cyto-plasmic domain with \u03b2and \u03b3-catenins and may be regulated by phosphorylation of \u03b2-catenin.Hereditary diffuse gastric carcinoma is an autosomal domi-nant cancer syndrome that results from germline mutations in the E-cadherin gene, CDH1. Carriers of CDH1 mutations have a 70% to 80% chance of developing gastric cancer.84"
        },
        {
            "id": "Pathology_Robbins_1270",
            "title": "Pathology_Robbins",
            "content": "In many forms of cancer, the growth-inhibiting effects of the TGF-\u03b2 pathways are impaired by mutations affecting TGF-\u03b2 signaling. These mutations may alter the type II TGF-\u03b2 receptor or SMAD molecules that serve to transduce anti-proliferative signals from the receptor to the nucleus. Mutations affecting the type II receptor are seen in cancers of the colon, stomach, and endometrium. Mutational inactivation of SMAD4, 1 of the 10 proteins known to be involved in TGF-\u03b2 signaling, is common in pancreatic cancers. In other cancers, by contrast, loss of TGF-\u03b2\u2013mediated growth control occurs at a level downstream of the core TGF-\u03b2 signaling pathway; for example, there may be loss of p21 expression and/or overexpression of MYC. These tumor cells can then use other elements of the TGF-\u03b2\u2013induced program, including immune system suppression or promotion of angiogenesis, to facilitate tumor progression. Thus, TGF-\u03b2 can function to prevent or promote tumor growth, depending on the state of other"
        },
        {
            "id": "InternalMed_Harrison_7147",
            "title": "InternalMed_Harrison",
            "content": "The desmoplastic stroma surrounding pancreatic adenocarcinoma functions as a mechanical barrier to chemotherapy and secretes compounds essential for tumor progression and metastasis. Key mediators of these functions include the activated pancreatic stellate cell and the glycoprotein SPARC (secreted protein acidic and rich in cysteine), which is expressed in 80% of pancreatic ductal adenocarcinomas. Targeting this extracellular environment has become increasingly important in the treatment of advanced disease."
        },
        {
            "id": "InternalMed_Harrison_7148",
            "title": "InternalMed_Harrison",
            "content": "Screening is not routinely recommended because the incidence of pancreatic cancer in the general population is low (lifetime risk 1.3%), putative tumor markers such as carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) have insufficient sensitivity, and computed tomography (CT) has inadequate resolution to detect pancreatic dysplasia. Endoscopic ultrasound (EUS) is a more promising screening tool, and preclinical efforts are focused on identifying biomarkers that may detect pancreatic cancer at an early stage. Consensus practice recommendations based largely on expert opinion have chosen a threshold of greater than fivefold increased risk for developing pancreatic cancer to select individuals who may benefit from screening. This includes people with two or more first-degree relatives with pancreatic cancer, patients with Peutz-Jeghers syndrome, and BRCA 2, p16, and hereditary nonpolyposis colorectal cancer (HNPCC) mutation carriers with one or more affected"
        },
        {
            "id": "Surgery_Schwartz_9788",
            "title": "Surgery_Schwartz",
            "content": "in an older adult patient with preexisting diabetes, should provoke concern for the presence of pancreatic cancer.Recent epidemiologic studies have confirmed the fact that patients with chronic pancreatitis, especially familial pan-creatitis, have an increased risk of developing pancreatic can-cer.124,196-198 Large, retrospective cohort studies of patients with pancreatitis have revealed up to a 20-fold increase in risk for pancreatic cancer. This increased risk seems to be independent of the type of pancreatitis, a finding consistent with the fact that most studies have shown little effect of alcohol ingestion per se Brunicardi_Ch33_p1429-p1516.indd 148401/03/19 6:46 PM 1485PANCREASCHAPTER 33on the risk of pancreatic carcinoma. The mechanisms involved in carcinogenesis in patients with preexisting pancreatitis are unknown. However, the mutated K-ras oncogene, which is pres-ent in most cases of pancreatic cancer, has been detected in the ductal epithelium of some patients with"
        },
        {
            "id": "Biochemistry_Lippincott_1197",
            "title": "Biochemistry_Lippinco",
            "content": "B. Dysfunctional \u03b2 cells In T2D, the pancreas initially retains \u03b2-cell capacity, resulting in insulin levels that vary from above normal to below normal. However, with time, the \u03b2 cell becomes increasingly dysfunctional and fails to secrete enough insulin to correct the prevailing hyperglycemia. For example, insulin levels are high in typical, obese, T2D patients but not as high as in similarly obese individuals who do not have diabetes. Thus, the natural progression of the disease results in a declining ability to control hyperglycemia with endogenous secretion of insulin (Fig. 25.10). Deterioration of \u03b2-cell function may be accelerated by the toxic effects of sustained hyperglycemia and elevated FFA and a proinflammatory environment. C. Metabolic changes The abnormalities of glucose and TAG metabolism in T2D are the result of insulin resistance expressed primarily in liver, skeletal muscle, and white adipose tissue (Fig. 25.11). 1."
        },
        {
            "id": "InternalMed_Harrison_27663",
            "title": "InternalMed_Harrison",
            "content": "Mutation prevents reception of satiety signal from MSH Mutation prevents synthesis of neuropeptide, probably MSH Same as above Hyperphagia due to uncharacterized hypothalamic defect (Fig. 415e-5). The results of genomewide association studies to identify genetic loci responsible for obesity in the general population have so far been disappointing. More than 40 replicated loci linked to obesity have been identified, but together they account for less than 3% of interindividual variation in BMI. The most replicated of these is a gene named FTO, which is of unknown function, but like many of the other recently described candidates, is expressed in the brain. Because the heritability of obesity is estimated to be 40\u201370%, it is likely that many more loci remain to be identified. It is possible that epistatic interactions between causative loci or unknown gene-environment interactions explain the poor success at identifying causal loci."
        },
        {
            "id": "Surgery_Schwartz_9674",
            "title": "Surgery_Schwartz",
            "content": "patients with advanced chronic pancreatitis referred for surgical therapy, indolent, undiagnosed carcinoma can be seen in as many as 10% of patients.199The development of carcinoma in the setting of chronic pancreatitis is no doubt related to the dysregulation of cellu-lar proliferation and tissue repair processes in the setting of chronic inflammation, as is seen throughout the alimentary tract and elsewhere. In the setting of chronic pancreatitis, car-cinoma development can be especially cryptic, and the diagno-sis of early-stage tumors is particularly difficult. Awareness of this risk justifies close surveillance for cancer in patients with chronic pancreatitis. Periodic measurement of tumor markers such as CA19-9, and periodic imaging of the pancreas with CT scan and EUS seem logical in order to detect the development Table 33-16Complications of chronic pancreatitisIntrapancreatic complications Pseudocysts Duodenal or gastric obstruction Thrombosis of splenic"
        },
        {
            "id": "Pathology_Robbins_1765",
            "title": "Pathology_Robbins",
            "content": "silencing of the other parental homologue by methylation of the promoter region located upstream of the transcription start site. Of all candidate \u201cWT2\u201d genes, imprinting abnormalities of insulinlike growth factor-2 (IGF2) have the strongest relationship to tumor predisposition in persons with BWS. IGF2 normally is expressed solely from the paternal allele, whereas the maternal allele is imprinted. In some Wilms tumors, loss of imprinting (i.e., reexpression of IGF2 by the maternal allele) can be demonstrated, leading to overexpression of the IGF2 protein, which is postulated to result in both organ enlargement and tumorigenesis. Thus, these associations suggest that in some cases, congenital malformations and tumors represent related manifestations of genetic lesions affecting a single gene or closely linked genes. In addition to Wilms tumors, patients with BWS also are at increased risk for the development of hepatoblastoma, adrenocortical tumors, rhabdomyosarcomas, and pancreatic"
        },
        {
            "id": "Pathology_Robbins_4101",
            "title": "Pathology_Robbins",
            "content": "no more than 5% of patients developing cancer at 20 years. In contrast, chronic pancreatitis that begins in childhood, such as hereditary pancreatitis secondary to PRSS1 mutations, confers a 40% to 55% lifetime risk for pancreatic cancer. It is not unusual for patients with PRSS1 mutations to undergo prophylactic pancreatectomy."
        },
        {
            "id": "Pathology_Robbins_4121",
            "title": "Pathology_Robbins",
            "content": "Typically,theseneoplasmsareductaladenocarcinomasthatproduceanintensedesmoplasticresponse. Mostpancreaticcancersarediagnosedatanadvancedstage,accountingforthehighmortalityrate. Obstructivejaundiceisafeatureofcarcinomaoftheheadofthepancreas;manypatientsalsoexperiencedebilitatingpain. Carcinomasofthetailofthepancreasareoftennotdetecteduntillateintheircourse. Andersen DK, Andren-Sandberg \u00c5, Duell EJ, et al: Pancreatitisdiabetes-pancreatic cancer: summary of an NIDDK-NCI workshop, Pancreas 42:1227\u20131237, 2013. [A white paper that summarizes the current state of evidence regarding the bidirectional and complex relationship between chronic pancreatitis or diabetes and pancreatic cancer. The recently described entity of pancreatogenic diabetes is also discussed.]"
        },
        {
            "id": "Pathology_Robbins_4115",
            "title": "Pathology_Robbins",
            "content": "been reported, and a growing number of inherited genetic defects are now recognized that increase pancreatic cancer risk. For example, germ line mutations of the familial breast/ ovarian cancer gene BRCA2 are seen in approximately 10% of cases arising in individuals of Ashkenazi Jewish heritage."
        },
        {
            "id": "Surgery_Schwartz_9793",
            "title": "Surgery_Schwartz",
            "content": "33-67). Three stages of pancreatic intraepithelial neoplasia have been defined. These lesions demonstrate the same oncogene mutations and loss of tumor-suppressor genes found in invasive cancers, the frequency of these abnormalities increasing with progressive cellular atypia and architectural disarray.313 The ability to detect these precursor lesions in humans at a stage where the cancer can still be prevented or cured is an important goal of current pancreatic cancer research.About two-thirds of pancreatic adenocarcinomas arise within the head or uncinate process of the pancreas; 15% are in the body, and 10% are in the tail, with the remaining tumors demonstrating diffuse involvement of the gland. Tumors in the pancreatic body and tail are generally larger at the time of diagnosis, and therefore, less commonly resectable. Tumors in the head of the pancreas are typically diagnosed earlier because they cause obstructive jaundice. Ampullary carci-nomas, carcinomas of the distal bile"
        },
        {
            "id": "Surgery_Schwartz_9798",
            "title": "Surgery_Schwartz",
            "content": "Topo\u02dc\u02dc\u00b0, 14-3-3\u02dbp53, DPC4, BRCA2Cyclin D1MesothelinMucin 1Mucin 1p16PSCA, Mucin5, FascinTelomere K-rasshorteningPanIN-3InvasionABCDFigure 33-67. Pancreatic intraepithelial neoplasia (PanIN). Histology (top panel) showing grades PanIN-1A (A), PanIN-1B (B), PanIN-2 (C), and PanIN-3 (D), and schema of correlation of histology with mutational events (bottom panel) showing cumulative abnormalities of tumor-promoter and tumor suppressor factors such as kRAS, p53, etc, and their corresponding cellular phenotype. (Reproduced with permis-sion from Hruban RH, Takaori K, Klimstra DS, et al: An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms, Am J Surg Pathol. 2004 Aug;28(8):977-987.)The most critical deficit in the ability to treat pancreatic cancer effectively is the lack of tools for early diagnosis. The pancreas is situated deep within the abdomen, and the early symptoms of pancreatic cancer often are too"
        },
        {
            "id": "InternalMed_Harrison_7144",
            "title": "InternalMed_Harrison",
            "content": "Pancreatic cancer is associated with a number of well-defined molecular hallmarks. The four genes most commonly mutated or inactivated in pancreatic cancer are KRAS (predominantly codon 12, in 60\u201375% of pancreatic cancers), the tumor-suppressor genes p16 (deleted in 95% of tumors), p53 (inactivated or mutated in 50\u201370% of tumors), and SMAD4 (deleted in 55% of tumors). The pancreatic cancer precursor lesion pancreatic intraepithelial neoplasia (PanIN) acquires these genetic abnormalities in a progressive manner associated with increasing dysplasia; initial KRAS mutations are followed by p16 loss and finally p53 and SMAD4 alterations. SMAD4 gene inactivation is associated with a pattern of widespread metastatic disease in advanced-stage patients and poorer survival in patients with surgically resected pancreatic adenocarcinoma."
        },
        {
            "id": "Surgery_Schwartz_9790",
            "title": "Surgery_Schwartz",
            "content": "suggesting that the presence of this mutation or others may provide the basis for diagnostic testing in select individuals. The HER2/neu oncogene, homolo-gous to the epidermal growth factor receptor (EGFr), is over-expressed in pancreatic cancers.310 This receptor is involved in signal transduction pathways that lead to cellular proliferation. Multiple tumor-suppressor genes are deleted and/or mutated in pancreatic cancer, including p53, p16, and DPC4 (Smad 4), and in a minority of cases, BRCA2.311 Most pancreatic cancers have three or more of the aforementioned mutations.The genetic landscape of pancreatic adenocarcinoma has recently been investigated using exome capture technol-ogy combined with the SOLiD or Illumina next generation sequencing platforms and copy number analysis. Detailed analysis of 99 tumors reaffirmed the importance of the already known mutations such as KRAS, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A, and SF3B1 in pancreatic cancer and identified eight novel"
        },
        {
            "id": "Pathology_Robbins_4122",
            "title": "Pathology_Robbins",
            "content": "Bailey P, Chang DK, Nones K, et al: Genomic analyses identify molecular subtypes of pancreatic cancer, Nature 531:47\u201352, 2016. [A comprehensive genomic profiling of pancreatic cancer by the International Cancer Genome Consortium.]. Dellinger EP, Forsmark CE, Layer P, et al: Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation, Ann Surg 256:875\u2013880, 2012. [An international classification system for the clinical severity of acute pancreatitis, which represents the consensus of opinions from physicians spanning 49 countries.] Hart PA, Zen Y, Chari ST: Recent advances in autoimmune pancreatitis, Gastroenterology 149:39\u201351, 2015. [An up-to-date review on the etiopathogenesis and clinical subtypes of autoimmune pancreatitis from one of the foremost expert groups on this subject.]"
        },
        {
            "id": "InternalMed_Harrison_7143",
            "title": "InternalMed_Harrison",
            "content": "Cigarette smoking may be the cause of up to 20\u201325% of all pancreatic cancers and is the most common environmental risk factor for this disease. A longstanding history of type 1 or type 2 diabetes also appears to be a risk factor; however, diabetes may also occur in association with pancreatic cancer, possibly confounding this interpretation. Other risk factors may include obesity, chronic pancreatitis, and ABO blood group status. Alcohol does not appear to be a risk factor unless excess consumption gives rise to chronic pancreatitis."
        },
        {
            "id": "Pathology_Robbins_4120",
            "title": "Pathology_Robbins",
            "content": "http://ebooksmedicine.net The clinical course of pancreatic carcinoma is rapidly progressive and often distressingly brief. Less than 20% of pancreatic cancers are resectable at the time of diagnosis. It has long been recognized that there is a profound need for biomarkers capable of detecting early, potentially curable, pancreatic cancers. Although serum levels of many enzymes and antigens (e.g., carcinoembryonic and CA19-9 antigens) are elevated, these markers are neither specific nor sensitive enough to be useful for screening. Several imaging techniques, such as endoscopic ultrasonography and high-resolution CT scans, are helpful for investigation in cases of suspected cancer but are not practical screening tests. Pancreaticcancerprobablyarisesfromnoninvasiveprecursorlesions(mostcommonly,PanINs),developingbyprogressiveaccumulationofmutationsofoncogenes(e.g.,KRAS)andtumorsuppressorgenes(e.g.,CDKN2A/p16,TP53, andSMAD4)."
        },
        {
            "id": "Pathology_Robbins_4109",
            "title": "Pathology_Robbins",
            "content": "http://ebooksmedicine.net Like all cancers, pancreatic cancer arises as a consequence of inherited and acquired mutations in cancer-associated Fig. 17.7 Intraductal papillary mucinous neoplasm. (A) Cross-section through the head of the pancreas showing a prominent papillary neoplasm distending the main pancreatic duct. (B) The papillary mucinous neoplasm involves the main pancreatic duct (left) and is extending down into the smaller ducts and ductules (right). genes. In a pattern analogous to that seen in the multi-step progression of colon cancer (Chapter 6), there is a progressive accumulation of genetic changes in pancreatic epithelium as it proceeds from nonneoplastic, to noninvasive precursor lesions, to invasive carcinoma ("
        }
    ],
    "scores": [
        0.02870063705399666,
        0.026793837144528702,
        0.025579560626289598,
        0.02530160049063248,
        0.02300054344400397,
        0.022356854359705393,
        0.021357808857808858,
        0.02107286576602472,
        0.020743168417587023,
        0.019327731092436976,
        0.018867924528301886,
        0.018268268268268266,
        0.017869964100518547,
        0.017551892551892552,
        0.016515330964600606,
        0.015258417942981703,
        0.01525768535262206,
        0.015172334821939769,
        0.015039523662868289,
        0.014961389961389961,
        0.01494107744107744,
        0.014775668679896463,
        0.014725786367819824,
        0.014709063378758382,
        0.014493506493506494,
        0.01438990735265129,
        0.014011589246698965,
        0.013874683150264598,
        0.013849557522123895,
        0.013811642565813867,
        0.013675213675213675,
        0.013623150678988243
    ]
}